NNC0195-0092

long-acting pegylated growth hormone · Novo Nordisk

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NNC0195-0092, covering 2026-01-16 to 2026-01-16. Get the full timeline:

Most recent: Clinical Trial Update: Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency [Phase 2]

See pricing